Susanna A McColley

  • 4671 Citations
1991 …2019
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

My clinical and research focus is cystic fibrosis. My research interests are developing new therapies, characterizing and treating early lung disease, and reducing outcomes disparities by identifying and treating children who are at higher risk for adverse outcomes. I am active in healthcare quality improvement at the practice and national level. Since newborn screening in cystic fibrosis has been established in the United States, I have been especially interested in refining care of the newly diagnosed infant and their family, and in bringing highly effective therapies into the care of infants. On the other end of the spectrum of pediatrics, I am engaged in research and program development in transition from pediatric to adult health care environments.

I specialize in pediatric lung disease, focusing on diagnosis and treatment of children with cystic fibrosis.

My major academic focus is therapeutic clinical trials. I also evaluate risk factors and health care system processes that contribute to disparate outcomes in cystic fibrosis. In my research leadership role, I enable trials in childhood-onset conditions.

Certifications and Licenses

Pediatric Pulmonology

Training Experience

1988Residency, Johns Hopkins Hospital
1991Fellowship, Johns Hopkins Hospital

Education/Academic qualification

MD, Northwestern University Feinberg School of Medicine

… → 1985

Keywords

  • Cystic Fibrosis
  • Health Disparities
  • Healthcare Quality
  • Pediatrics

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Cystic Fibrosis Medicine & Life Sciences
Lung Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Pulmonary Medicine Medicine & Life Sciences
Cystic Fibrosis Transmembrane Conductance Regulator Medicine & Life Sciences
Obstructive Sleep Apnea Medicine & Life Sciences
Pseudomonas Infections Medicine & Life Sciences
Forced Expiratory Volume Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2010 2018

Research Output 1991 2019

Surgical Splenorenal Shunt
Portal Hypertension
Cystic Fibrosis
Transplants
Liver
1 Citation (Scopus)

Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics

Levy, H., Jia, S., Pan, A., Zhang, X., Kaldunski, M., Nugent, M. L., Reske, M., Feliciano, R. A., Quintero, D., Renda, M. M., Woods, K. J., Murkowski, K., Johnson, K., Verbsky, J., Dasu, T., Ideozu, J. E., McColley, S. A., Quasney, M. W., Dahmer, M. K., Avner, E. & 5 othersFarrell, P. M., Cannon, C. L., Jacob, H., Simpson, P. M. & Hessner, M. J., Jan 1 2019, In : Physiological genomics. 51, 1, p. 27-41 15 p.

Research output: Contribution to journalArticle

Genomics
Cystic Fibrosis
Genes
Blood Cells
Flow Cytometry

Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition

Southern, K. W., Barben, J., Gartner, S., Munck, A., Castellani, C., Mayell, S. J., Davies, J. C., Winters, V., Murphy, J., Salinas, D., McColley, S. A., Ren, C. L. & Farrell, P. M., Jan 1 2019, In : Journal of Cystic Fibrosis.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV 1

McColley, S. A., Konstan, M. W., Ramsey, B. W., Stuart Elborn, J., Boyle, M. P., Wainwright, C. E., Waltz, D., Vera-Llonch, M., Marigowda, G., Jiang, J. G. & Rubin, J. L., Jan 1 2019, In : Journal of Cystic Fibrosis. 18, 1, p. 94-101 8 p.

Research output: Contribution to journalArticle

Lung
Placebos
Forced Expiratory Volume
ivacaftor drug combination lumacaftor
Cystic Fibrosis
3 Citations (Scopus)

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

McNamara, J. J., McColley, S. A., Marigowda, G., Liu, F., Tian, S., Owen, C. A., Stiles, D., Li, C., Waltz, D., Wang, L. T. & Sawicki, G. S., Apr 1 2019, In : The Lancet Respiratory Medicine. 7, 4, p. 325-335 11 p.

Research output: Contribution to journalArticle

Cystic Fibrosis
Pharmacokinetics
Safety
Therapeutics
Sweat